Survodutide uk Peptide

Description

Survodutide (BI 456906) is an investigational unimolecular dual agonist developed by Boehringer Ingelheim (licensed from Zealand Pharma) that activates both the glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR). Based on a modified glucagon backbone with C18 fatty acid acylation supporting once-weekly dosing, it is currently being evaluated in Phase 3 clinical trials (SYNCHRONIZE program) and represents an area of active incretin receptor research. This research-grade lyophilized powder is synthesized under strict quality controls and provided with full analytical documentation. For Research Use Only. Not for human use.

Key Scientific Attributes

• High-purity Survodutide (≥98% by HPLC/MS, acetate salt form)
• Verified 29-amino-acid glucagon-based sequence with C18 diacid lipidation
• Lyophilized formulation for maximum long-term stability
• Full Certificate of Analysis (COA) with HPLC, MS, receptor-binding assays (GLP-1R/GCGR EC50), and endotoxin testing
• Manufactured in GMP-aligned, ISO-compliant facilities
• Suitable for dual-agonist receptor signaling studies and related in vitro pathway research